Potential Upcoming Advances in Fragile X Research

February 3, 2022

Dr. Peter Kind and Dr. Nahum Sonenberg share their optimism about the next 10 years of Fragile X research. They discuss where they think the next big discoveries will emerge.

Read More »

Pharmacotherapeutic Effects of Cannabidiol (CBD) in Fragile X syndrome (FXS) and Autism Spectrum disorder (ASD)

May 6, 2021

This study tested CBD (cannabidiol) treatment in male and female Fragile X mice to learn how and why it works and whether gender affects responses to CDB treatment.

Read More »

Metformin and Aberrant Insulin Signaling in a Fragile X Mouse Model

November 2, 2018

FRAXA-funded research is revealing how insulin signaling is altered in Fragile X and whether lowering it, including with metformin, could ease symptoms.

Read More »
Nahum Sonenberg

Effects of Metformin in Fmr1 Knockout Mouse Model of Fragile X Syndrome

November 8, 2017

Metformin, a safe diabetes drug, activates AMPK to rebalance protein synthesis. FRAXA-funded work investigated its potential to treat Fragile X.

Read More »
18th International Fragile X and Related Neurodevelopmental Disorders Workshop, Quebec, Canada

In Their Own Words: Reports From the International Fragile X Workshop

October 29, 2017

The 18th International Fragile X Workshop in Quebec was a great success, featuring more Fragile X research than ever before!

Read More »
Nahum Sonenberg, PhD, 2017 Fragile X Research Grant

Metformin, Diabetes Drug, Potential Fragile X Treatment

May 18, 2017

Dr. Nahum Sonenberg’s research showed the diabetes drug metformin can correct key signaling defects in Fragile X, leading to clinical trials of this safe, repurposed therapy.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (37)